Nov 7th, 2018 - ASH News Daily is the official print publication of the ASH annual meeting. View an archive of recent ASH News Daily publications
Nov 21st, 2018 - Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.
Nov 23rd, 2018 - The premier event in hematology is celebrating its diamond anniversary. This will be the 60th annual meeting of the American Society of Hematology (ASH). It will be returning to the city of San Diego, California, and will run from November 30 to December 4.
Nov 21st, 2018 - As part of the Education Program at the 2018 ASH annual meeting, three physician-writers will offer their take on the intersection of storytelling, writing, and medicine – asking why doctors should care about the narrative, how the patient narrative informs treatment decisions, and how writing can be a tool for advocacy and change.
Nov 21st, 2018 - The “Trainee Day” that attendees may know from past annual meetings has been reimagined as ASH-a-Palooza – a new educational experience that will offer a relaxed, open learning environment for trainees in a festival-like setting with multiple opportunities for micro-learning. During breaks between sessions at Petco Park, trainees can enjoy ballpark-style food and are invited to visit informatio...
Nov 21st, 2018 - John E. Dick, PhD, recipient of the 2018 Mentor Award in basic science, tells us about his career in the lab – from working at “the mecca of stem-cell research” to learning how to foster creativity in his own lab
Nov 7th, 2018 - The premier event in malignant and non-malignant hematology, the ASH annual meeting highlights the highest-caliber science and the most important areas of clinical progress in hematology.
Nov 21st, 2018 - Ibrutinib and checkpoint inhibitors may improve the efficacy of chimeric antigen receptor (CAR) T-cell therapies, according to investigators in two separate studies.
Nov 27th, 2018 - Ahead of the conference, multiple myeloma experts Sundar Jagannath, MBBS, and Ajai Chari, MD, selected the most pivotal abstracts in their field
Nov 12th, 2017 - The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies presented at ASH.
Nov 12th, 2017 - A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multice...
Oct 12th, 2017 - Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.
Oct 12th, 2017 - The anti-CCR4 monoclonal antibody mogamulizumab reduced the risk of progression or death by 47% compared with vorinostat (Zolinza) in previously treated patients with cutaneous T-cell lymphoma.
Dec 1st, 2018 - The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.
Combination regimens in CLL are already impressive, but new combinations currently being evaluated have strong potential to be even better.
Sep 12th, 2017 - The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.
Nov 12th, 2017 - New longer-term data on CAR T cells in patients with refractory and relapsed (R/R) lymphoma show that responses are durable, with about half of patients alive after a year or more.
Dec 12th, 2017 - The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Nov 12th, 2017 - The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.